GlobeNewswire Inc.··Rosen Law FirmImmutep Stock Plummets 82.6% After Failed Phase III Trial; Class Action Lawsuit Looms
Immutep's stock crashed after discontinuing Phase III TACTI-004 trial for eftilagimod alfa due to futility, prompting securities litigation against the biotech firm.
IMMPinvestor lossessecurities class action